Markham & Read Announces $600,000 Federal Jury Award to Orange County Businessman Bruce Cahill Following Verdict of Fraud and Libel against Paul P. Edalat
Boston-based law firm Markham & Read today announced that in the case of Bruce Cahill et. al. versus Paul Pejman Edalat et. al. (U.S. Federal Court Docket: 8:16-cv-00686), a federal jury has determined that Edalat deliberately acted with oppression, fraud or malice toward Cahill, the former CEO by of Pharma Pak, Inc. who claimed Edalat had launched a smear campaign against him on social media over a year-long period.
The jury issued an award of $600,000 in damages suffered by Cahill and ruled that Edalat is liable for punitive damages. A hearing will take place in U.S. District Court, Central District of California (Santa Ana division) on August 22nd to determine the extent of punitive damages.
The jury also found that Edalat was liable for damages to Pharma Pak investors Greg Cullen, Ron Franco and Shane Scott.
“We are pleased that the jury sent a clear message to Paul Edalat while fully supporting Bruce Cahill and his longstanding good reputation in the community,” said John J. Markham, attorney for Cahill and the Pharma Pak investors. “The verdict and resulting damages are proof positive that Mr. Cahill was completely vindicated against Edalat’s unscrupulous actions and defamatory statements, along with others who the jury determined were damaged by Edalat.”
During the trial, Markham and attorney Bridget A. Zerner set forth evidence and testimony showing that Edalat induced more than $4 million of investment into Pharma Pak from Cahill, Cullen, Franco, Scott and others by making numerous claims regarding the company’s value, its intellectual property, its existing customer base and roster of prospective clients.
Throughout the proceedings, jurors heard direct evidence that Edalat, an Orange County native who previously filed bankruptcy in Southern California (U.S. Bankruptcy Court Docket: 8:14-bk-14529-TA) and in 2014 was “permanently restrained and enjoined … from directly or indirectly manufacturing, preparing, packing, labeling, holding, or distributing any dietary supplements” by the U.S. District Court for the Central District of California (U.S. Federal Court Docket: SACV 14-01759-JLS), used investment money to pay for gambling debts in Las Vegas and other lavish expenses. They also reviewed many postings Edalat made on social media regarding the former Pharma Pak CEO’s personal life, which formed the basis of Mr. Cahill’s claims in court that Edalat sought to defame him after litigation was filed in federal court.
Further, the jury ruled that Edalat’s co-defendant, Olivia Karpinski, was liable for $11,000 in damages to Cahill based on defamatory claims she made on social media.
During the trial, the jury heard the testimony of an Irvine police officer that discredited Karpinski’s attempt to falsely claim that she was a victim of sexual battery. Karpinski went to the Irvine Police Department on October 13, 2016, the day before she was deposed in the case and filed a report (Irvine CA Police Department Record #16-15720) claiming she was the victim of “stalking” and returned to the station two hours later to make an additional claim of sexual battery. According to the report, the officer explained her account was not sexual battery and questioned why she waited 11 months to report the allegations. Karpinski had previously posted the false battery claims against Cahill on her Instagram account, where they remained visible to the public for several months.
“As an entrepreneur and philanthropist in Southern California for over 30 years, I am grateful that the jury acknowledged my reputation as an honest, successful businessman in sectors such as technology, semiconductors, publishing, and real estate industries,” said Cahill. “I’m also pleased that they recognized the damages caused by the numerous false claims and defamatory statements made against me by Paul Edalat.”
Scott Farmelant/Jill Reilly
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28 | Tiedote
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme